Summary & Overview
HCPCS Q4229: Cogenex Amniotic Membrane, Per Square Centimeter
HCPCS Level II code Q4229 designates Cogenex amniotic membrane billed per square centimeter as an add-on supply reported alongside a primary surgical or wound-care procedure. The code identifies a biologic allograft product used in tissue repair, ocular, dermatologic, or reconstructive procedures where an amniotic membrane is applied. Nationally, payers and providers use this code to track utilization and apply product-level reimbursement rules separate from primary procedural payments.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical contexts in which the product is used, typical sites of service, and the role of an add-on HCPCS code for documenting product usage. The analysis also outlines which payers commonly acknowledge product-level HCPCS reporting and where policy variation or prior authorization requirements can affect coverage and billing.
This publication provides benchmarks for code usage, summaries of relevant payer policy positions when available, and clinical context for coding accuracy. Data not available in the input is noted where applicable; the content focuses on national billing practice and payer engagement rather than state-specific guidance.
Billing Code Overview
HCPCS Level II code Q4229 describes Cogenex amniotic membrane, billed per square centimeter. This entry-level description designates the product as an add-on supply intended to be reported in addition to a primary procedure that uses an amniotic membrane graft or biologic matrix.
Service Type: Amniotic membrane graft / biologic implant supply
Typical Site of Service: Outpatient surgical settings, hospital outpatient departments, ambulatory surgery centers, and specialty clinics where wound care or reconstructive procedures using amniotic membrane are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a nonhealing surgical or chronic wound (for example, a diabetic foot ulcer, venous stasis ulcer, or complex soft tissue defect after debridement) who is undergoing application of an amniotic membrane product as an adjunct to standard wound care. The procedure is performed in an outpatient wound clinic, ambulatory surgery center, or hospital outpatient department. Clinical workflow: the wound is assessed, debrided if needed, hemostasis achieved, and the wound bed prepared. The provider selects an appropriate size of Q4229 (amniotic membrane, billed per square centimeter) to cover the wound; the product is trimmed to fit, placed on the wound surface, and secured with appropriate dressings or sutures. Post-application care includes dressing changes, infection monitoring, and scheduled follow-up visits to assess graft take and wound healing progress.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity is substantially greater than typical for the primary procedure to which the amniotic membrane is an add-on. |
52 |